OakChart

enVVeno Medical Corp

NVNOHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 3:58 PM ET

6.52+0.07 (1.09%)
2026-11-12 06:34 CET
Market cap
4.53 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-15.55 USD m
Free cash flow, TTM
-13.41 USD m
EPS diluted, TTM
-23.45
P/E
-
Compare

Price

NVNO against its 20, 50 and 200-day averages
2050200earnings
10.0020.0030.0096K191KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NVNOclose 6.5220-day 7.0150-day 8.30200-day 10.126.5252w high

73.4% under the 52-week high of 24.50 on 12 Nov 2025. 52-week low 6.26 on 6 Nov 2026. Last 15 sessions, 23.6% high to low

Volume 0.19× normal · the line is the 50-bar volume average

Profile

NVNO
52-week range, 1% of the way up
6.2624.50

enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include VenoValve and enVVe. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

Employees33
IPOMay 31, 2018
Beta1.38
ATR, 14d0.72
Rel volume0.19
Short float3.60%
Insider own2.93%
Inst own13.05%

Snapshot

6 groups

Valuation

Index-
Market Cap4.53M
Enterprise Value-13.53M
Income-15.55M
Sales0.00M
Book/sh24.32
Cash/sh26.59
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees33
IPOMay 31, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.27
P/C0.25
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio7.35
Current Ratio7.35
Debt/Eq0.02
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-23.45
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y24.52% 34.00%
Sales past 3/5Y- -
EPS Y/Y TTM40.73%
Sales Y/Y TTM-
EPS Q/Q20.17%
Sales Q/Q-
EarningsOct 30 BMO
EPS/Sales Surpr.-92.35% -

Ownership

Insider Own2.93%
Insider Trans-0.74%
Inst Own13.05%
Inst Trans-9.88%
ROA-60.00%
ROE-67.11%
ROIC-92.02%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-6.98%
SMA50-21.45%
SMA200-35.58%
Trades-

Technical

Shs Outstand0.69M
Shs Float0.67M
Short Float3.60%
Short Ratio0.80
Short Interest0.02M
52W High24.50 -73.39%
52W Low6.26 4.15%
Volatility11.39% 9.83%
ATR (14)0.72
RSI (14)36.27
Beta1.38
Rel Volume0.19
Avg Volume30.05K
Volume5,833

Performance

Perf Week-6.86%
Perf Month-18.19%
Perf Quarter-39.94%
Perf Half Y-31.01%
Perf YTD-41.93%
Perf Year-73.15%
Perf 3Y-95.89%
Perf 5Y-97.67%
Perf 10Y-
Recom1.00
Target Price30.00
Prev Close6.45
Price6.52
Change %1.09%

Peers

Mkt cap
TickerCompanyMkt cap
NSPRInspireMD Inc37.19M
AVRAnteris Technologies Global Corp604.46M
LMATLemaitre Vascular Inc1.81B
ADGMAdagio Medical Holdings Inc1.71M
AORTArtivion Inc980.68M
ANGOAngiodynamic Inc522.32M
PMIPicard Medical Inc19.77M
CVRXCVRx Inc19.95M
PENPenumbra Inc12.68B
TCMDTactile Systems Technology Inc607.74M

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Duhay FrancisDirectorSep 11 '26Sale11.21111232,351Sep 14 06:56 PM
Duhay FrancisDirectorSep 11 '26Proposed Sale11.1811123Sep 11 10:20 AM
Duhay FrancisDirectorJun 11 '26Sale10.301401,4432,362Jun 12 04:05 PM
Duhay FrancisDirectorJun 11 '26Proposed Sale10.311401,443Jun 11 11:16 AM
Duhay FrancisDirectorMar 12 '26Sale11.521401,6132,502Mar 13 04:05 PM
Duhay FrancisDirectorMar 12 '26Proposed Sale11.521401,613Mar 12 12:13 PM
Duhay FrancisDirectorDec 11 '25Sale0.364,9001,74292,544Dec 12 04:40 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium (ACCESSWIRE)
  • enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal Study (ACCESSWIRE)
  • enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob Berman (ACCESSWIRE)
  • enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial (ACCESSWIRE)
  • enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series (ACCESSWIRE)
  • enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand (ACCESSWIRE) -5.67%
  • enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference (ACCESSWIRE)
  • Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments (ACCESSWIRE)
  • enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve (ACCESSWIRE)
  • enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment (ACCESSWIRE)
  • enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial (ACCESSWIRE)
  • enVVeno Medical to Present in the Webull Corporate Connect Webinar Series (ACCESSWIRE) +5.00%
  • enVVeno Medical to Participate in the Virtual Investor Closing Bell Series (ACCESSWIRE)
  • enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment (ACCESSWIRE) -5.67%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-30-6.290-3.270-0.000.001
2026Q22026-07-31-5.370-4.690-5.3650.000.001
2026Q12026-05-04-5.880--5.8850.00--
2025Q22025-07-31-11.550-9.800-11.5120.000.001
2025Q12025-05-05-7.700-11.900-7.7440.000.001
2024Q42025-02-27-10.882-12.250-12.4320.000.001
2024Q32024-11-07-12.250-11.550-12.2900.000.001
2024Q22024-07-30-10.850--10.7960.00--
2024Q12024-05-09-10.850-14.000-10.8810.000.001
2023Q32023-10-26-15.750-16.800-15.5850.000.001
2023Q22023-08-08-20.300-17.150-20.1750.000.001
2023Q12023-04-28-19.950-16.800-19.9200.000.001
2022Q42023-03-02-19.600-19.600-22.8360.000.001
2022Q32022-10-27-18.900--19.0040.00-1
2022Q22022-08-03-22.050-11.550-22.0120.000.001
2022Q12022-05-02-16.450-10.150-16.6130.000.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-1,531-1,365-1,5280.190.24
2020FY-263.9-297.5-264.040.000.00
2021FY-66.500--66.6460.00-
2022FY-77.000-77.000-76.8850.000.00
2023FY-61.950-61.950-66.9100.000.00
2024FY-44.450-46.200-0.000.00
2025FY--37.800-33.059-0.00
2026FY--35.000--7.00
2027FY--25.900--16.80
2028FY--16.450--28.72

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-07-311000.000.000.00
2026Q4S2026-07-031000.000.000.00
2026Q4E2026-07-31100-2.35-2.35-2.35
2026Q4E2026-07-03100-2.35-2.35-2.35
2026Q3S2026-07-311000.000.000.00
2026Q3S2026-07-031000.000.000.00
2026Q3S2025-08-131002.252.252.25
2026Q3S2025-08-121002.252.252.25
2026Q3S2025-08-111002.252.252.25
2026Q3S2025-08-101002.252.252.25
2026Q3S2025-08-091002.252.252.25
2026Q3S2025-08-081002.252.252.25
2026Q3S2025-08-071002.252.252.25
2026Q3S2025-08-061002.252.252.25

Estimate history

EPS, annual-627.428-1528.293-423.351-264.036-66.646-76.885-66.91-44.549-33.059-23.452
Period201720182019202020212022202320242025TTM
EPS, quarterly-12.29-12.432-7.744-11.512-7.882-5.909-5.885-5.365-6.293
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.4220.1870.0310000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0130.0130.020.0730.2710.2710.380.5010.6560.695
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.5010.5010.5010.550.5780.6560.6560.6730.695
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.030.19
Cost of Goods Sold Incl. D&A0.380.490.530.550.530.450.38--
Gross Profit-0.38-0.49-0.53-0.55-0.53-0.45-0.38--
Selling, General and Administrative Excl. Other16.0220.4123.3024.6924.4116.448.756.727.59
Research and Development9.019.9812.2513.589.915.734.252.211.24
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-16.41-20.90-23.83-25.24-24.93-16.89-9.14-7.09-7.54
Interest Expense0.000.000.000.000.000.00-0.006.86
Unusual Expense0.170.390.02-0.47-0.05-0.31-0.210.59-1.35
Net Income Before Taxes-15.55-19.47-21.82-23.52-24.67-16.53-9.14-7.63-13.04
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-15.55-19.47-21.82-23.52-24.67-16.53-9.14-7.63-13.04
Net Income From Continuing Operations-15.55-19.47-21.82-23.52-24.67-16.53-9.14-7.63-13.04
Net Income-15.55-19.47-21.82-23.52-24.67-16.53-9.74-7.63-16.35
EPS (Recurring)-22.24-32.59-44.52-67.84-76.99-67.53-268.05-400.47-1,616.83
EPS (Basic, Before Extraordinaries)-23.45-33.06-44.55-66.91-76.88-66.65-264.04-423.35-1,528.29
EPS (Diluted)-23.45-33.06-44.55-66.91-76.88-66.65-264.04-423.35-1,528.29
EBITDA-16.02-20.41-23.30-24.69-24.41-16.44-8.75-6.69-7.40
Non-Operating Income (Expense)1.021.822.031.250.210.05-0.210.050.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.913.424.145.209.006.000.680.490.86
Price To Sales Ratio-------277.4574.03
Operating Margin--------22,681.85-4,039.17
Net Margin--------24,406.74-8,765.77
Shares Outstanding0.690.660.500.380.270.270.070.020.01
Market Capitalization4.534.5352.9648.6948.3162.4121.989.8617.29

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.110.030.120.120.120.130.120.12
Gross Profit-0.11-0.03-0.12-0.12-0.12-0.13-0.12-0.12
Selling, General and Administrative Excl. Other4.423.773.943.904.766.924.836.58
Research and Development2.882.082.111.952.582.892.563.51
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.53-3.80-4.06-4.01-4.88-7.05-4.95-6.70
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.020.020.040.080.040.080.190.12
Net Income Before Taxes-4.37-3.60-3.85-3.74-4.54-6.69-4.50-6.23
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.37-3.60-3.85-3.74-4.54-6.69-4.50-6.23
Net Income From Continuing Operations-4.37-3.60-3.85-3.74-4.54-6.69-4.50-6.23
Net Income-4.37-3.60-3.85-3.74-4.54-6.69-4.50-6.23
EPS (Recurring)-6.27-5.34-5.84-5.82-7.83-11.42-7.51-12.27
EPS (Basic, Before Extraordinaries)-6.29-5.37-5.89-5.91-7.88-11.51-7.74-12.43
EPS (Diluted)-6.29-5.37-5.89-5.91-7.88-11.51-7.74-12.43
EBITDA-4.42-3.77-3.94-3.90-4.76-6.92-4.83-6.58
Non-Operating Income (Expense)0.190.220.260.360.380.430.650.59
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.410.400.470.640.691.440.651.02
Shares Outstanding0.690.670.660.660.580.550.500.50
Market Capitalization4.537.156.647.3718.3276.8046.1252.96

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments28.2143.1546.4139.0454.739.331.312.740.08
Short Term Receivables0.000.000.000.000.000.000.000.030.04
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.610.580.510.390.310.230.120.060.06
Total Current Assets28.8343.7346.9239.4455.049.571.422.840.17
Net Property, Plant & Equipment0.701.191.682.192.600.941.170.030.02
Total Investments and Advances0.000.000.000.000.000.000.810.000.00
Intangible Assets------0.000.671.11
Other Assets0.030.030.030.030.050.030.030.030.91
Total Assets29.5644.9548.6341.6657.7010.543.433.562.21
Short Term Debt Incl. Current Port. of LT Debt0.390.360.340.310.290.630.290.002.62
Accounts Payable0.361.010.000.650.561.391.221.081.45
Other Current Liabilities1.370.721.030.570.731.170.370.410.92
Total Current Liabilities2.122.101.371.531.583.191.881.494.99
Long Term Debt0.310.701.061.401.710.250.570.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.033.18
Total Liabilities2.432.792.442.933.293.442.441.528.17
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.005.17
Common Equity27.1342.1646.2038.7354.407.100.992.04-11.13
Total Shareholders Equity27.1342.1646.2038.7354.407.100.992.04-5.96
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity27.1342.1646.2038.7354.407.100.992.04-5.96
Total Liabilities & Stockholders Equity29.5644.9548.6341.6657.7010.543.433.562.21
Book Value Per Share41.3684.14121.42143.11201.0797.7548.30152.00-846.34
Tangible Book Value Per Share41.3684.14121.42143.11201.0797.7548.30102.26-930.70
Full-Time Employees33373130241912--
Price to Book Ratio0.271.261.951.131.153.109.968.495.06
Return on Assets-52.26-46.63-52.09-49.66-48.44-130.77-218.07-451.75-389.79
Return on Equity-56.21-49.39-55.38-52.98-53.75-225.91-503.93--
Return on Invested Capital-70.96-50.91-49.75-61.47-29.45-124.27-489.47-640.47-
Quick Ratio13.5820.8834.2325.7834.833.000.761.900.03
Current Ratio13.5820.8834.2325.7834.833.000.761.900.03

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-15.55-19.47-21.82-23.52-24.67-16.53-9.14-7.63-13.04
Depreciation0.380.490.530.550.530.450.380.400.13
Other Funds (Non Cash)2.083.814.164.738.955.690.701.537.13
Funds from Operations-13.09-15.17-17.13-18.24-15.20-10.39-8.05-5.70-5.78
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.32-0.400.29-0.62-0.42-1.460.38-0.20-0.58
Cash from Operating Activities-13.41-15.57-16.84-18.86-15.62-11.85-7.68-5.90-6.36
Capital Expenditures0.00-0.01-0.04-0.03-0.12-0.37-0.18-0.36-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments13.3515.861.37-7.83-34.440.000.000.000.00
Purchase of Investments-75.97-46.02-55.57-56.52-48.130.000.000.000.00
Sale Or Maturity of Investments89.3361.8856.9448.6913.690.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities13.3515.861.33-7.87-34.55-0.37-0.18-0.36-0.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock1.091.0213.6425.790.0057.6114.765.646.95
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock1.091.0213.6425.790.0057.6114.765.646.95
Proceedsfrom Stock Options1.090.7813.5925.790.0057.3611.785.646.95
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.310.002.08
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities1.091.0213.6425.790.0057.6115.075.649.03
Net Change in Cash1.041.31-1.87-0.94-50.1745.397.22-0.622.66
Free Cash Flow-13.41-15.57-16.88-18.89-15.73-12.21-7.86-6.26-6.37
Preferred Dividends (Cash Flow)-0.000.000.000.000.00-0.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments18.4721.4924.9328.2130.9535.14
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.550.600.560.610.550.46
Total Current Assets19.0222.0825.4928.8331.5035.60
Net Property, Plant & Equipment0.440.550.580.700.820.94
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.030.030.030.030.030.03
Total Assets19.4922.6626.1029.5632.3536.58
Short Term Debt Incl. Current Port. of LT Debt0.410.400.400.390.290.38
Accounts Payable1.080.540.810.360.631.07
Other Current Liabilities1.100.940.931.371.491.56
Total Current Liabilities2.591.892.142.122.403.02
Long Term Debt0.000.100.210.310.510.51
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities2.591.992.352.432.903.52
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity16.9020.6723.7527.1329.4533.06
Total Shareholders Equity16.9020.6723.7527.1329.4533.06
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity16.9020.6723.7527.1329.4533.06
Total Liabilities & Stockholders Equity19.4922.6626.1029.5632.3536.58
Book Value Per Share24.3230.7136.2041.3650.9860.11
Tangible Book Value Per Share24.3230.7136.2041.3650.9860.11
Full-Time Employees---33--
Price to Book Ratio0.270.300.240.270.622.32
Return on Assets-60.00-53.09-56.45-52.26-53.09-59.48
Return on Equity-67.11-58.53-60.65-56.21-57.19-64.55
Return on Invested Capital-25.84-17.33-16.07-13.62-15.15-19.95
Quick Ratio7.3511.7011.8913.5813.1211.81
Current Ratio7.3511.7011.8913.5813.1211.81

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-4.37-3.60-3.85-3.74-4.54-6.69
Depreciation0.110.030.120.120.120.13
Other Funds (Non Cash)0.430.420.510.720.731.52
Funds from Operations-3.82-3.15-3.21-2.90-3.69-5.04
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.65-0.40-0.03-0.54-0.701.33
Cash from Operating Activities-3.18-3.55-3.24-3.44-4.39-3.71
Capital Expenditures0.000.000.000.000.00-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments2.733.672.774.183.652.83
Purchase of Investments-15.84-18.57-22.24-19.32-9.89-7.93
Sale Or Maturity of Investments18.5822.2425.0123.5013.5510.76
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities2.733.672.774.183.652.82
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.190.130.000.780.240.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.190.130.000.780.240.00
Proceedsfrom Stock Options0.190.130.000.780.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.190.130.000.780.240.00
Net Change in Cash-0.260.24-0.471.52-0.50-0.89
Free Cash Flow-3.18-3.55-3.24-3.44-4.39-3.72

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.60%0.0M0.7M28.11K
2026-10-151.76%0.0M0.7M24.98K
2026-09-302.02%0.0M0.7M22.84K
2026-09-151.40%0.0M0.7M20.99K
2026-08-311.32%0.0M0.6M16.18K
2026-08-143.87%0.0M0.6M15.37K
2026-07-312.90%0.0M0.6M13.94K
2026-07-151.78%0.0M0.6M12.85K
2026-06-301.77%0.0M0.6M10.44K
2026-06-152.42%0.0M0.6M11.14K
2026-05-2911.48%0.1M0.6M13.27K
2026-05-1511.66%0.1M0.6M14.17K
2026-04-309.90%0.1M0.6M16.39K
2026-04-1512.69%0.1M0.6M20.88K
2026-03-3112.45%0.1M0.6M21.59K
2026-03-1313.32%0.1M0.6M22.28K
2026-02-2712.41%0.1M0.6M20.19K
2026-02-1313.75%0.1M0.6M24.66K
2026-01-3012.04%0.1M0.6M21.77K
2026-01-1510.93%0.1M0.6M15.99K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13G/ASEC
2026-10-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-12-10SEC
2026-09-15SCHEDULE 13D/ASEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-21S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-14SCHEDULE 13G/ASEC
2026-07-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-148-KCurrent report2026-07-14SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-11144Filing for proposed sale of securities under Rule 144.SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-298-KCurrent report2026-04-29SEC
2026-03-26S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-2610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-134Statement of changes in beneficial ownership of securities2026-03-12SEC
2026-03-12144Filing for proposed sale of securities under Rule 144.SEC
2026-02-20SCHEDULE 13DSEC
2026-02-20SCHEDULE 13DSEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-10SCHEDULE 13GSEC
2026-02-10SCHEDULE 13GSEC
2026-02-048-KCurrent report2026-02-04SEC
2026-01-208-KCurrent report2026-01-20SEC
2025-12-184Statement of changes in beneficial ownership of securities2025-12-16SEC
2025-12-184Statement of changes in beneficial ownership of securities2025-12-16SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09001231
2026-080000
2026-070000
2026-06001.44K1
2026-050000
2026-040000
2026-03001.61K1
2026-020000
2026-010000
2025-12001.74K1
2025-110000

Institutional holders

Manager% owned
KINGDON CAPITAL MANAGEMENT, L.L.C.5.42%
CM Management, LLC5.35%
VANGUARD CAPITAL MANAGEMENT LLC0.94%
JPMORGAN CHASE & CO0.78%
VANGUARD FIDUCIARY TRUST CO0.33%
UBS Group AG0.28%
Westside Investment Management, Inc.0.22%
Mirae Asset Global Investments Co., Ltd.0.08%
BlackRock, Inc.0.06%
Tower Research Capital LLC0.05%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.94%
Fidelity Extended Market Index Fund0.48%
Fidelity Total Market Index Fund0.12%
Fidelity Series Total Market Index Fund0.12%
Fidelity Nasdaq Composite Index Fund0.03%

OakChart. NVNO. Cached 15 minutes.

Some panels did not load: ratings.